Aclaris Therapeutics (ACRS) said Tuesday it has obtained clearance to proceed with a phase 1a/1b clinical trial of its monoclonal antibody ATI-052, which is being developed to treat certain immuno-inflammatory diseases, from the US Food and Drug Administration.
The clinical trial will assess single and multiple ascending doses of ATI-052, followed by a proof-of-concept portion in an undisclosed indication, the company said.
Aclaris said it expects to start the trial in Q2.
Price: 1.14, Change: +0.01, Percent Change: +0.88
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。